Medpace demonstrates strong financial performance and growth in the CRO market, despite facing challenges in the short term. Read why MEDP stock is a Strong Buy.

The company's robust balance sheet and growth prospects are noted, but not enough to justify a market-beating performance.

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...

Truist Advisory Services' chief market strategist Keith Lerner says the "carousel of tariffs" and DeepSeek-related headlines have upended markets, but things could get much rockier as he urges clients ...

Microchip Technology's revenue has been declining for four consecutive quarters. Read more to see why I'm very bearish on ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...